Optimal dose, timing and ratio of blood products in massive transfusion: results from a systematic review ZK McQuilten, G Crighton, S Brunskill, JK Morison, TH Richter, N Waters, ... Transfusion medicine reviews 32 (1), 6-15, 2018 | 119 | 2018 |
Assessment of the urgency and deferability of transfusion to inform emergency blood planning and triage: the Bloodhound prospective audit of red blood cell use J Shortt, MN Polizzotto, N Waters, M Borosak, M Moran, M Comande, ... Transfusion 49 (11), 2296-2303, 2009 | 60 | 2009 |
Profiling clinical platelet and plasma use to inform blood supply and contingency planning: PUPPY, the prospective utilization of platelets and plasma study PL Fedele, MN Polizzotto, G Grigoriadis, N Waters, M Comande, ... Transfusion 56 (10), 2455-2465, 2016 | 31 | 2016 |
Demographic and socio-cultural correlates of medical mistrust in two Australian States: Victoria and South Australia A Renzaho, M Polonsky, Z McQuilten, N Waters Health & place 24, 216-224, 2013 | 29 | 2013 |
Factors leading to health care exclusion among African refugees in Australia: the case of blood donation MJ Polonsky, AS Ferdous, AMN Renzaho, N Waters, Z McQuilten Journal of Public Policy & Marketing 37 (2), 306-326, 2018 | 26 | 2018 |
The cost of blood: a study of the total cost of red blood cell transfusion in patients with β‐thalassemia using time‐driven activity‐based costing ZK McQuilten, AM Higgins, K Burns, S Chunilal, T Dunstan, HE Haysom, ... Transfusion 59 (11), 3386-3395, 2019 | 17 | 2019 |
A time‐driven, activity‐based costing methodology for determining the costs of red blood cell transfusion in patients with beta thalassaemia major KE Burns, HE Haysom, AM Higgins, N Waters, R Tahiri, K Rushford, ... Transfusion Medicine 29 (1), 33-40, 2019 | 16 | 2019 |
Major haemorrhage fatalities in the Australian national coronial database JS Gipson, EM Wood, MF Cole‐Sinclair, Z McQuilten, N Waters, ... Emergency Medicine Australasia 30 (3), 382-388, 2018 | 11 | 2018 |
Blood donation by A frican migrants and refugees in A ustralia: the role of demographic and socio‐economic factors Z McQuilten, N Waters, M Polonsky, A Renzaho Vox sanguinis 106 (2), 137-143, 2014 | 11 | 2014 |
Rational: A randomised controlled feasibility trial comparing prophylactic immunoglobulin with antibiotics in patients with acquired hypogammaglobulinemia secondary to … Z McQuilten, R Weinkove, P Crispin, A Degelia, C Dendle, M Gilbertson, ... Lippincott Williams and Wilkins, 2021 | 2 | 2021 |
Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy ZK McQuilten, R Weinkove, LTP Thao, P Crispin, A Degelia, C Dendle, ... Blood Advances 8 (7), 1787-1795, 2024 | 1 | 2024 |
Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND … Z McQuilten, S Heritier, L Fox, V Fox, L Young, P Blombery, I Cunningham, ... BMJ open 14 (1), e076246, 2024 | 1 | 2024 |
Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia-the Diaamond-Ava-First and … Z McQuilten, LC Fox, V Fox, S Heritier, TJ Batt, P Blombery, J Curnow, ... Blood 140 (Supplement 1), 2931-2932, 2022 | 1 | 2022 |
Understanding and meeting clinical platelet requirements: an analysis of indications and urgency of platelet use from the prospective utilisation of platelets and plasma (Puppy … N Polizzotto, N Waters, M Comande, G Grigoriadis, M Borosak, D Jolley HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 94, 455-456, 2009 | 1 | 2009 |
The establishment of a multiple myeloma clinical registry in the Asia–Pacific region: The Asia–Pacific Myeloma and Related Diseases Registry (APAC MRDR) N Aoki, PY Chen, W Chen, WJ Chng, GG Gan, YT Goh, J Hou, J Huang, ... BMC Medical Research Methodology 24 (1), 1-11, 2024 | | 2024 |
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies S Carrillo De Albornoz, AM Higgins, D Petrie, A Irving, L Fanning, ... Blood Advances, bloodadvances. 2023012047, 2024 | | 2024 |
Protocol: Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the … Z McQuilten, S Heritier, L Fox, V Fox, L Young, P Blombery, I Cunningham, ... BMJ Open 14 (1), 2024 | | 2024 |
Sickle cell disease in Australia: a snapshot from the Australian Haemoglobinopathy Registry A Nelson, PJ Ho, H Haysom, N Waters, C Wellard, M Chee, J Teo, ... Internal Medicine Journal, 2023 | | 2023 |
Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II … EM Wood, KL Chai, J Reynolds, J Griffiths, B Beaton, J Callum, ... Blood 142, 1295, 2023 | | 2023 |
Tranexamic Acid to Prevent Bleeding in Patients with Hematologic Malignancies and Severe Thrombocytopenia (TREATT trial). a Randomized Placebo-Controlled Trial LJ Estcourt, ZK McQuilten, P Bardy, M Cole-Sinclair, GP Collins, ... Blood 142, 702, 2023 | | 2023 |